Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Peer Review reports

Original Submission
20 Aug 2018	Submitted	Original manuscript
23 Sep 2018	Reviewed	Reviewer Report - Renata Duchnowska
3 Oct 2018	Reviewed	Reviewer Report - Judith Bliss
12 Oct 2018	Author responded	Author comments - Joaquín Gavila
Resubmission - Version 2
12 Oct 2018	Submitted	Manuscript version 2
1 Nov 2018	Reviewed	Reviewer Report - Judith Bliss
12 Nov 2018	Author responded	Author comments - Joaquín Gavila
Resubmission - Version 3
12 Nov 2018	Submitted	Manuscript version 3
Publishing
10 Dec 2018	Editorially accepted
9 Jan 2019	Article published	10.1186/s12916-018-1233-1

Back to article page